文献速递肿瘤 PET/CT神经核医学

神经母细胞瘤个体化风险评估:治疗前123I-MIBG SPECT肿瘤代谢活性能否预测结局

Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-14

该回顾性研究纳入23例初诊神经母细胞瘤患儿,于治疗前行123I-MIBG SPECT,以半自动阈值定义原发肿瘤代谢体积(MTV)及其非球度(ASP)。单因素Cox分析显示ASP、MTV和MYCN扩增状态是事件无生存(EFS)的显著预测因子,ASP与MTV高低组EFS差异有统计学意义;ASP或MTV联合尿HVA/C的联合风险模型预测EFS最佳。

要点

  • 治疗前123I-MIBG SPECT衍生的ASP和MTV与神经母细胞瘤患儿EFS相关。
  • 高ASP(>32.0%)组平均EFS为21个月,低ASP组为88个月(p=0.013)。
  • 高MTV(>46.7 ml)组平均EFS为22个月,低MTV组为87个月(p=0.023)。

核心结论

  • 在这项探索性研究中,治疗前影像衍生的肿瘤代谢活性标志物(ASP、MTV)和实验室标志物(尿HVA/C)可识别当前治疗下进展/复发高风险与低风险的患儿。

研究设计与样本

  • 回顾性研究纳入23例初诊神经母细胞瘤患儿(11例女孩、12例男孩;中位年龄1.8岁,范围0.3-6.8岁),连续行治疗前123I-MIBG SPECT检查。
  • 采用半自动阈值定义原发肿瘤MTV和ASP;对ASP、MTV、实验室参数(包括尿HVA/C)、临床因素(年龄、分期)和遗传因素行Cox回归、ROC分析(确定截断值)及Kaplan-Meier分析和log-rank检验(EFS)。
  • 以Harrell's C和似然比χ²确定最佳多因素模型的预测准确性。

主要发现

  • 中位随访36个月(范围7-107个月),8例患者出现疾病进展/复发,4例死亡。
  • 单因素Cox回归中EFS的显著预测因子仅为ASP(p=0.029;每增加一个单位HR 1.032)、MTV(p=0.038;HR 1.012)和MYCN扩增状态(p=0.047;HR 4.67)。
  • 高ASP(>32.0%)组与低ASP组平均EFS分别为21个月和88个月(p=0.013);高MTV(>46.7 ml)组与低MTV组平均EFS分别为22个月和87个月(p=0.023)。
  • 高ASP且高HVA/C或高MTV且高HVA/C的联合风险模型对EFS的预测最佳。

关键数值与推荐

  • ASP截断值>32.0%,高ASP组平均EFS 21个月 vs 低ASP组88个月(p=0.013)。
  • MTV截断值>46.7 ml,高MTV组平均EFS 22个月 vs 低MTV组87个月(p=0.023)。
  • 单因素Cox回归:ASP每增加一个单位HR 1.032(p=0.029);MTV每增加一个单位HR 1.012(p=0.038);MYCN扩增状态HR 4.67(p=0.047)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Risk-adapted treatment in children with neuroblastoma (NB) is based on clinical and genetic factors. This study evaluated the metabolic tumour volume (MTV) and its asphericity (ASP) in pretherapeutic 123I-MIBG SPECT for individualized image-based prediction of outcome. METHODS: This retrospective study included 23 children (11 girls, 12 boys; median age 1.8 years, range 0.3-6.8 years) with newly diagnosed NB consecutively examined with pretherapeutic 123I-MIBG SPECT. Primary tumour MTV and ASP were defined using semiautomatic thresholds. Cox regression analysis, receiver operating characteristic analysis (cut-off determination) and Kaplan-Meier analysis with the log-rank test for event-free survival (EFS) were performed for ASP, MTV, laboratory parameters (including urinary homovanillic acid-to-creatinine ratio, HVA/C), and clinical (age, stage) and genetic factors. Predictive accuracy of the optimal multifactorial model was determined in terms of Harrell's C and likelihood ratio χ 2. RESULTS: Median follow-up was 36 months (range 7-107 months; eight patients showed disease progression/relapse, four patients died). The only significant predictors of EFS in the univariate Cox regression analysis were ASP (p = 0.029; hazard ratio, HR, 1.032 for a one unit increase), MTV (p = 0.038; HR 1.012) and MYCN amplification status (p = 0.047; HR 4.67). The mean EFS in patients with high ASP (>32.0%) and low ASP were 21 and 88 months, respectively (p = 0.013), and in those with high MTV (>46.7 ml) and low MTV were 22 and 87 months, respectively (p = 0.023). A combined risk model of either high ASP and high HVA/C or high MTV and high HVA/C best predicted EFS. CONCLUSIONS: In this exploratory study, pretherapeutic image-derived and laboratory markers of tumoral metabolic activity in NB (ASP, MTV, urinary HVA/C) allowed the identification of children with a high and low risk of progression/relapse under current therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rogasch JMM, Hundsdoerfer P, Furth C, et al. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome? Eur J Nucl Med Mol Imaging. 2017. PMID: 28808732. doi:10.1007/s00259-017-3786-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。